GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Short-Term Capital Lease Obligation

Halberd (Halberd) Short-Term Capital Lease Obligation : $0.00 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Short-Term Capital Lease Obligation?

Halberd's Short-Term Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.00 Mil.


Halberd Short-Term Capital Lease Obligation Historical Data

The historical data trend for Halberd's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Short-Term Capital Lease Obligation Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Short-Term Capital Lease Obligation
- - -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Short-Term Capital Lease Obligation - - -

Halberd Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Halberd Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Halberd's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Industry
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236